FY2025 EPS Estimates for Oculis Lifted by Leerink Partnrs

Oculis Holding AG (NASDAQ:OCS) – Equities researchers at Leerink Partnrs increased their FY2025 earnings estimates for Oculis in a research note issued to investors on Tuesday, November 11th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($2.38) per share for the year, up from their previous estimate of ($2.51). The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for Oculis’ Q4 2025 earnings at ($0.50) EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($3.63) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at $0.06 EPS.

Several other equities research analysts have also issued reports on OCS. HC Wainwright lifted their price target on Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and issued a $51.00 price target on shares of Oculis in a research note on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of Oculis in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.80.

Oculis Stock Performance

Oculis stock opened at $19.29 on Friday. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $23.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.55 and a current ratio of 4.47. The stock has a market cap of $1.01 billion, a P/E ratio of -7.65 and a beta of 0.30. The firm’s fifty day moving average price is $19.15 and its 200-day moving average price is $18.62.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Pivotal bioVenture Partners Investment Advisor LLC raised its position in Oculis by 32.4% during the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock valued at $43,784,000 after purchasing an additional 563,078 shares during the last quarter. SR One Capital Management LP bought a new position in shares of Oculis during the first quarter valued at approximately $6,137,000. Aberdeen Group plc lifted its stake in Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock worth $23,847,000 after acquiring an additional 243,695 shares during the period. Alyeska Investment Group L.P. bought a new stake in Oculis in the first quarter valued at $2,499,000. Finally, Marshall Wace LLP purchased a new position in Oculis during the 2nd quarter valued at $393,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.